LOTUSEYE Stock Overview
Lotus Eye Hospital and Institute Limited, ein Augenkrankenhaus, bietet Augenpflege und damit verbundene Dienstleistungen in Indien an.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Lotus Eye Hospital and Institute Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹61.55 |
| 52 Week High | ₹111.00 |
| 52 Week Low | ₹48.50 |
| Beta | 0.30 |
| 1 Month Change | -11.63% |
| 3 Month Change | -29.05% |
| 1 Year Change | -4.05% |
| 3 Year Change | 38.78% |
| 5 Year Change | 186.28% |
| Change since IPO | 72.65% |
Recent News & Updates
Recent updates
Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06Shareholder Returns
| LOTUSEYE | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 10.6% | 2.2% | 3.2% |
| 1Y | -4.1% | 71.0% | 48.9% |
Rendite im Vergleich zur Industrie: LOTUSEYE unter dem Niveau der Branche Indian Healthcare , die im vergangenen Jahr eine Rendite von 72.9% erzielte.
Rendite vs. Markt: LOTUSEYE hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 19.4 erzielte.
Price Volatility
| LOTUSEYE volatility | |
|---|---|
| LOTUSEYE Average Weekly Movement | 12.0% |
| Healthcare Industry Average Movement | 6.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.2% |
Stabiler Aktienkurs: LOTUSEYEDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: LOTUSEYEDie wöchentliche Volatilität (8%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75% der Indian Aktien.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 313 | Kuttapalayam Ramalingam | https://www.lotuseye.org |
Lotus Eye Hospital and Institute Limited, ein Augenkrankenhaus, bietet Augenpflege und damit verbundene Dienstleistungen in Indien an. Das Unternehmen bietet Dienstleistungen in den Bereichen Katarakt, refraktive Chirurgie, Netzhauterkrankungen und diabetische Augenpflege, Uvea und Augenentzündungen, Hornhautinfektionen, Glaukom, Computer Vision Syndrom, Orbita und Oculoplastik, Neuro-Ophthalmologie, Augenprothesen, Binokularsehen, Keratokonus und Zyoptix ultimate an und betreibt eine Augenbank. Darüber hinaus bietet das Unternehmen verschiedene Kurse für Augenoptiker sowie DNB-Schulungsdienste an.
Lotus Eye Hospital and Institute Limited Fundamentals Summary
| LOTUSEYE fundamental statistics | |
|---|---|
| Market cap | ₹1.28b |
| Earnings (TTM) | ₹35.38m |
| Revenue (TTM) | ₹484.95m |
36.2x
P/E Ratio2.6x
P/S RatioIs LOTUSEYE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOTUSEYE income statement (TTM) | |
|---|---|
| Revenue | ₹484.95m |
| Cost of Revenue | ₹343.46m |
| Gross Profit | ₹141.50m |
| Other Expenses | ₹106.12m |
| Earnings | ₹35.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.70 |
| Gross Margin | 29.18% |
| Net Profit Margin | 7.30% |
| Debt/Equity Ratio | 0.7% |
How did LOTUSEYE perform over the long term?
See historical performance and comparison